← All trials
NCT06087913
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 8, 2023
- Primary completion
- Oct 31, 2024
- Completion date
- Jun 30, 2025
- First posted
- Oct 18, 2023
- Last posted
- Dec 13, 2023
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Eastern Virginia Medical SchoolLead sponsor
- CONRADCollaborator
- Centre for the AIDS Programme of Research in South AfricaCollaborator
- Centre for the AIDS Programme of Research in South AfricaStudy chair
- University of PittsburghCollaborator
- Kenya Medical Research InstituteCollaborator
- Kenya Medical Research InstituteStudy chair
- United States Agency for International DevelopmentCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.